Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPR119 | Q8TDV5 | 20/20 | 0.55 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.54 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12261635 | 0.86 | GPR119 (0.57) | GPR119CYP2C9KCNH2 | |
| SCHEMBL13058678 | 0.85 | GPR119 (0.63) | GPR119CYP2C9KCNH2 | |
| SCHEMBL288503 | 0.84 | GPR119 (0.57) | GPR119CYP2C9KCNH2 | |
| SCHEMBL12236465 | 0.83 | GPR119 (0.56) | GPR119CYP2C9KCNH2 | |
| SCHEMBL12236466 | 0.82 | GPR119 (0.55) | GPR119CYP2C9KCNH2 | |
| SCHEMBL12236406 | 0.82 | GPR119 (0.64) | GPR119CYP2C9KCNH2 | |
| SCHEMBL20375463 | 0.80 | GPR119 (0.71) | GPR119CYP2C9KCNH2 | |
| SCHEMBL13107758 | 0.80 | GPR119 (0.74) | GPR119CYP2C9 | |
| SCHEMBL23866615 | 0.78 | GPR119 (0.70) | GPR119CYP2C9KCNH2 | |
| SCHEMBL12258475 | 0.77 | GPR119 (0.65) | GPR119CYP2C9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8362248-B2 | Substituted pyridinyl and pyrimidinyl derivatives as modulators of metabolism and the treatment of disorders related thereto | ARENA PHARMACEUTICALS, INC. (US) | 2013-01-29 | — | — | US | disclosed |
| US-20070167473-A1 | Substituted pyridinyl and pyrimidinyl derivatives as modulators of metabolism and the treatment of disorders related thereto | ARENA PHARMACEUTICALS, INC. | 2007-07-19 | — | — | US | disclosed |
| US-20070078150-A1 | Substituted pyrindinyl and pyrimidinyl derivatives as modulators of metabolism and the treatment of disorders related thereto | ARENA PHARMACEUTICALS, INC. (US) | 2007-04-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070078150-A1 | Substituted pyrindinyl and pyrimidinyl derivatives as modulators of metabolism and the treatment of disorders related thereto | PC, GPR119, PNPO | GPR119 2/4885CYP2C9 208/4885KCNH2 4647/4885 |
| US-20070167473-A1 | Substituted pyridinyl and pyrimidinyl derivatives as modulators of metabolism and the treatment of disorders related thereto | PLPBP, PNPO, PDXK | GPR119 7/4885CYP2C9 253/4885KCNH2 4517/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.